SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-038522
Filing Date
2024-02-16
Accepted
2024-02-16 16:32:37
Documents
18
Period of Report
2024-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d729040d8k.htm   iXBRL 8-K 33229
2 EX-1.1 d729040dex11.htm EX-1.1 319565
3 EX-5.1 d729040dex51.htm EX-5.1 17859
4 EX-99.1 d729040dex991.htm EX-99.1 10533
8 GRAPHIC g729040g0215144858892.jpg GRAPHIC 3966
  Complete submission text file 0001193125-24-038522.txt   608626

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA kalv-20240214.xsd EX-101.SCH 2853
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20240214_lab.xml EX-101.LAB 17994
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20240214_pre.xml EX-101.PRE 11263
19 EXTRACTED XBRL INSTANCE DOCUMENT d729040d8k_htm.xml XML 3648
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 24648918
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)